Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon

You'll hear cautious optimism about cardiovascular benefits with the SGLT2 inhibitor, empagliflozin (Jardiance)....

Get unlimited access through an Enterprise license

Hospital Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals